Monitor for FDA acceptance of the resubmission and subsequent PDUFA date assignment, expected within 30 days. If accepted, a decision by late 2026 would be the next major catalyst. The stock has a history of strong positive reactions to regulatory progress on relacorilant.
CORT drugs
CORT drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 18 $79.91entry
- T+1 · 5mo ago −0.25%α +0.06% · $79.71
- T+5 · 5mo ago +6.06%α +7.72% · $84.75
- T+20 · 4mo ago +12.28%α +11.74% · $89.72
- T+60 · 2mo ago +39.91%α +38.01% · $111.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Corcept Therapeutics resubmitted its New Drug Application (NDA) to the FDA for relacorilant as a treatment for Cushing's syndrome, including additional analyses requested by the agency. The NDA is based on positive Phase III data from the GRACE and GRADIENT trials, and the company expects a six-month review. This represents a key step toward potential label expansion for a drug already approved in ovarian cancer, but approval is not guaranteed.
Key Facts
- NDA for relacorilant (Cushing's syndrome) resubmitted to FDA on June 17, 2026.
- Resubmission includes additional analyses of prior data as requested by the FDA.
- Corcept expects a six-month review cycle (~6 months).
- Positive data from pivotal GRACE trial, Phase III GRADIENT trial, and long-term extension study support the NDA.
Financial Impact
Not specified
Risk Factors
- FDA may request additional clinical data or deny approval.
- Competition from existing Cushing's therapies (e.g., Korlym, Isturisa) may limit market share.
- Six-month review timeline could extend if FDA issues a complete response letter.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-274258 |
| Document: d159941dex991.htm | 0001193125-26-274258 |
| Document: 0001193125-26-274258-index-headers.html | 0001193125-26-274258 |
| Document: 0001193125-26-274258-index.html | 0001193125-26-274258 |
| Document: 0001193125-26-274258.txt | 0001193125-26-274258 |
Track record
36 reports on CORT
7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
- Oct 5, 20266w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
- Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers